...
首页> 外文期刊>Journal of the European Academy of Dermatology and Venereology: JEADV >Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.
【24h】

Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.

机译:局部卡泊三醇,倍他米松二丙酸酯及其组合治疗局部性白癜风的效果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Treatment of vitiligo is a challenge. Steroids are known to be effective but are associated with serious adverse effects. Many uncontrolled studies have shown calcipotriol to be a promising therapeutic modality in vitiligo. OBJECTIVE: To conduct a randomized trial to evaluate the effect of topical calcipotriol ointment (0.005%) and betamethasone dipropionate (0.05%) cream, given alone or in combination, in treatment of localized vitiligo. METHODS: Forty-nine patients with vitiligo affecting 5% of their skin were recruited. Patients were randomized into three groups. Group I patients were treated with betamethasone dipropionate (0.05%) cream twice daily. Group II patients were treated with calcipotriol ointment (0.005%) twice daily, and group III with betamethasone dipropionate (0.05%) in the morning and calcipotriol (0.005%) in the evening. RESULTS: Forty-five patients completed the study period of 3 months with 15 patients in each group. No patient achieved excellent (> 75%) pigmentation. Marked (50% to 75%) repigmentation was observed in 2 (13.3%), 1 (6.7%) and 4 (26.7%) patients in groups I, II and III, respectively. Moderate (25-50%) repigmentation was observed in 7 (46.7%), 5 (33.3%) and 7 (46.7%) patients in groups I, II and III, respectively. Patients with < 25% pigmentation were termed as minimal pigmentation or no response. The mean time for initial pigmentation to appear was 9.04 +/- 2.0 weeks in group I, 10.18 +/- 1.6 weeks in group II and 5.17 +/- 2.4 weeks in group III (P < 0.01). The acquired pigmentation in the lesions was more stable in group III as compared with patients in groups II and I (P < 0.01). Side-effects in the form of atrophy and lesional burning sensations were more common in group I when compared with groups II and III (P < 0.05). CONCLUSION: Combined therapy appeared to give a significantly faster onset of repigmentation along with better stability of the achieved pigmentation and with lesser number of side-effects.
机译:背景:白癜风的治疗是一个挑战。已知类固醇是有效的,但与严重的不良反应有关。许多未经控制的研究表明卡泊三醇是白癜风的一种有前途的治疗方法。目的:进行一项随机试验,以评估局部或联合使用卡泊三醇软膏(0.005%)和倍他米松双丙酸酯(0.05%)乳膏治疗局部性白癜风的效果。方法:招募了49例白癜风患者,其皮肤的5%受到影响。将患者随机分为三组。 I组患者每天接受两次丙酸倍他米松(0.05%)乳膏治疗。 II组患者每天两次用卡泊三醇软膏(0.005%)进行治疗,III组患者在早晨用倍他米松二丙酸酯(0.05%)和晚上用卡泊三醇(0.005%)治疗。结果:45例患者完成了为期3个月的研究,每组15例。没有患者获得优异的色素沉着(> 75%)。 I,II和III组分别有2名(13.3%),1名(6.7%)和4名(26.7%)患者出现明显的(50%至75%)色素沉着。 I,II和III组分别有7位(46.7%),5位(33.3%)和7位(46.7%)的患者出现了中度(25-50%)的色素沉着。色素沉着少于25%的患者被称为色素沉着最少或无反应。 I组出现初始色素沉着的平均时间为9.04 +/- 2.0周,II组为10.18 +/- 1.6周,III组为5.17 +/- 2.4周(P <0.01)。与II组和I组相比,III组的病变中获得的色素沉着更加稳定(P <0.01)。与II组和III组相比,I组以萎缩和病灶灼热感为形式的副作用更为常见(P <0.05)。结论:联合疗法似乎使色素沉着的发生明显加快,同时获得的色素沉着具有更好的稳定性,且副作用较少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号